Lichen planus: a comprehensive evidence‐based analysis of medical treatment

Husein‐ElAhmed, Husein; Gieler, Uwe; Steinhoff, Martin

doi:10.1111/jdv.15771

Cited by 60 publications

(110 citation statements)

References 205 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…OLP patients show periods of disease exacerbation and remission; therefore, treatment focuses on helping severe lesions heal, reducing pain or other discomforts (Husein-ElAhmed et al, 2019).…”

mentioning

confidence: 99%

Photobiomodulation is effective in oral lichen planus: A randomized, controlled, double‐blind study

et al. 2020

View full text Add to dashboard Cite

Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous disease, affecting 1%-2% of the population at middle age, with a discrete female predominance (Anuradha et al., 2008;Gupta et al., 2013). OLP aetiology is unknown but evidence suggests that this disease is an immune-mediated process orchestrated by CD 4+ and CD 8+ T lymphocytes as well as by diverse inflammatory cytokines that lead to the apoptosis of epithelial cells (Kurago, 2016;Payeras et al., 2013).Reticular OLP represents the most frequent clinical presentation, characterized by interlaced striae, called Wickham's striae, and hyperkeratotic papules and plaques, usually asymptomatic

show abstract

mentioning

confidence: 99%

Photobiomodulation is effective in oral lichen planus: A randomized, controlled, double‐blind study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…intralesional glucocorticoid injections [65]. At the same time it has limited significance in other forms of lichen planus [66].…”

Section: Mechanizm I Efekty Działaniamentioning

confidence: 99%

The place of hydroxychloroquine in modern dermatology

Dańczak‐Pazdrowska¹,

Polańska²

2021

View full text Add to dashboard Cite

Hydroxychloroquine has been known since the 1940s. It was initially used to treat malaria. Currently, it has a well-established position in the treatment of lupus erythematosus. The knowledge about its benefits is increasing over time. The mechanism of action of hydroxychloroquine reaches far beyond the immunomodulatory effect, and includes a beneficial effect on glycemic control in patients with diabetes and it is believed to have an effect on normalization of lipid levels, including total cholesterol, LDL cholesterol and triglycerides. In treatment of lupus erythematosus hydroxychloroquine allows decreasing the dose of immunosuppressive drugs, thus not only increasing the treatment efficacy, but also reducing the risk of adverse effects. Possible indications for hydroxychloroquine include also granulomatous skin diseases, such as disseminated annular granuloma, cutaneous sarcoidosis, or reactive granulomatous dermatitis. This article discusses the current indications for hydroxychloroquine with focus on recommended therapeutic regimens and monitoring treatment. streszczenie Hydroksychlorochina jest lekiem znanym od lat 40. ubiegłego wieku. Początkowo stosowano ją w leczeniu malarii, a później tocznia rumieniowatego. Obecnie ma ugruntowaną pozycję w terapii tego ostatniego schorzenia. Jednocześnie znanych jest coraz więcej korzyści płynących ze stosowania leku. Wykraczają one daleko poza działanie immunomodulujące, obejmując liczne aspekty zespołu metabolicznego, a wdrożenie hydroksychlorochiny do leczenia umożliwia ograniczenie dawek leków immunosupresyjnych, nie tylko zwiększając skuteczność, lecz także zmniejszając ryzyko wystąpienia działań niepożądanych. We współczesnej dermatologii, poza schorzeniami z kręgu autoimmunizacyjnych chorób tkanki łącznej, coraz częściej rekomendowana jest w innych chorobach, np. ziarniniakowych. W pracy omówiono aktualne wskazania do leczenia hydroksychlorochiną, zwracając szczególną uwagę na zalecane schematy terapeutyczne i postępowanie monitorujące leczenie, mające poprawiać bezpieczeństwo stosowania leku.

show abstract

“…The pathogenesis of CLP is not fully elucidated. The central phenomenon underlying the appearance of CLP lesions is the cell-mediated immune response in basal keratinocytes, which subsequently become a source of antigens that can trigger the immune response [ 33 ]. The main cells involved are helper T cells, cytotoxic T cells, natural killer cells (NK), and dendritic cells.…”

Section: Introductionmentioning

confidence: 99%

Oxidative Stress in Cutaneous Lichen Planus—A Narrative Review

Georgescu

Mitran

et al. 2021

JCM

View full text Add to dashboard Cite

Lichen planus (LP) is a chronic, immune-mediated inflammatory skin condition that mainly affects the skin (cutaneous LP, CLP) and oral mucosa (oral LP, OLP). However, the mechanisms involved in the pathogenesis of the disease are not fully elucidated. Over time, several theories that could explain the appearance of LP lesions have been postulated. The key players in LP pathogenesis are the inflammatory infiltrate consisting of T cells and the proinflammatory cytokines. The cytokines stimulate the production of reactive oxygen species that induce cell apoptosis, a defining element encountered in LP. The lead inquiry triggered by this revolves around the role of oxidative stress in LP development. There are currently numerous studies showing the involvement of oxidative stress in OLP, but in terms of CLP, data are scarce. In this review, we analyze for the first time the currently existing studies on oxidative stress in CLP and summarize the results in order to assess the role of oxidative stress in skin lesions offering a fresher updated perspective.

show abstract

Lichen planus: a comprehensive evidence‐based analysis of medical treatment

Cited by 60 publications

References 205 publications

Photobiomodulation is effective in oral lichen planus: A randomized, controlled, double‐blind study

Photobiomodulation is effective in oral lichen planus: A randomized, controlled, double‐blind study

The place of hydroxychloroquine in modern dermatology

Oxidative Stress in Cutaneous Lichen Planus—A Narrative Review

Contact Info

Product

Resources

About